INNO-LiPA® HLA-A Update

Detects all known alleles of HLA-A with one amplification and two strips

INNO-LiPA HLA-A Update is a line probe assay for the molecular typing of human leukocyte antigen (HLA) A alleles at allele group level (A*01–A*80).

    CE marked
    INNO-LiPA® HLA-A Update

    Product number 80332

    20 Tests
    INNO-LiPA® HLA-A Update

    Product number 80688

    100 Tests
    INNO-LiPA® HLA-A Update Multiplex

    Product number 80333

    20 Tests
    INNO-LiPA® HLA-A Update Multiplex

    Product number 80689

    100 Tests
    Please contact your local Fujirebio representative for the availability of this product in your country.

    Click here to navigate

    • Details
    • Conditions of sale
    • Citations
    • Documentation
    • Insights
    • Related products
    • Details

      Features & Benefits

      More informative than serology

      • INNO-LiPA HLA-A Update yields more information on genetic variation
      • New alleles mainly appear as new probe patterns, not blanks
      • Null alleles can be detected

      Convenient

      • Reagents are synthesized and are therefore not limited in quantity
      • Reagents are standardized to show minimal batch-to-batch differences
      • INNO-LiPA HLA-A Update utilizes DNA samples that are easy to transport
      • Cell viability or surface expression is not important
      • Two strips replace multiple testing

      Rapid

      • INNO-LiPA HLA-A Update can be used for emergency typing as well as for large batch analysis
      • One technician – one to one hundred samples – one working day

      Simple

      • The LiPA technique is easy to perform
      • Automation is possible using TENDIGO® and Auto-LiPA™ 48
      • Objective interpretation of data with LiRAS® for LiPA HLA software
    • Conditions of sale

      To read the end user conditions of sale for this product please visit our Resource center.

    • Citations

      The BIOZ badges associated with Fujirebio products include peer-reviewed citations derived from scientific studies using Fujirebio products. Please note that the peer-reviewed citations do not reflect the regulatory status of Fujirebio products. Users should refer to the specific product documentation and any (clinical) claims made therein in order to ensure compliant use. For each country or geographic region, users must verify the related regulatory status of the Fujirebio product.

    • Insights